echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The Production Process of methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate

    The Production Process of methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate

    • Last Update: 2023-05-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The Production Process of methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate involves a multi-step synthetic process that involves a variety of chemical reactions and purification steps.


    The synthesis of this compound, which is also known as Cyclosporine A, typically begins with the synthesis of the cyclopropane ring, which is a key structural element of the molecule.
    This is typically accomplished through a series of reactions that involve the formation of a cyclopropanecarbaldehyde intermediate, followed by reduction to form the cyclopropane ring.


    Next, the synthesis of the quinoxaline ring is typically accomplished through a series of reactions that involve the formation of a quinoxaline-1,2-dicarbaldehyde intermediate, followed by reduction to form the quinoxaline ring.
    The tert-butyl and methoxy groups are then introduced through a series of intermediate steps, followed by the introduction of the carboxylate group at the end of the synthesis process.


    The production process of Cyclosporine A is a complex and multi-step synthesis that involves a variety of chemical reactions and purification steps.
    The final product is a white to off-white powder that is soluble in organic solvents and has a melting point in the range of 160-165°C.
    The molecule has a complex and highly functionalized structure, with a wide range of pharmaceutical properties and potential therapeutic applications.


    Overall, the production process of methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate is a challenging and complex synthetic process that requires a high degree of technical expertise and specialized equipment.
    However, the final product has the potential to provide important therapeutic benefits for a wide range of diseases and conditions.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.